Novartis profit declines as competition hits cancer drug sales
Novartis’s third-quarter earnings excluding some items fell 3% to $1.23 a share from $1.27 a year earlier
Latest News »
- Cyberattack hits UK Parliament, limiting access to MPs’ emails
- Narendra Modi will convey Indian IT firms’ role in US to Trump: Vishal Sikka
- Gujarat Congress leader Shankarsinh Vaghela hits out at party leadership
- Yogi Adityanath govt launches ‘informer scheme’ to curb female foeticide
- World Taekwondo Federation changes its name over ‘negative’ acronym
London: Novartis AG, Europe’s second-biggest drugmaker by sales, said profit fell for the seventh straight quarter as generic competition eroded sales of blockbuster cancer treatment Gleevec.
Third-quarter earnings excluding some items fell 3% to $1.23 a share from $1.27 a year earlier, the Basel, Switzerland-based company said Tuesday in a statement. Analysts estimated $1.20, according to data compiled by Bloomberg.
Novartis, also grappling with a slump at its eye-care division Alcon, is banking on newer treatments like heart medicine Entresto and Cosentyx for psoriasis. Chief executive officer Joe Jimenez in July called the two drugs catalysts over the next five years. Bloomberg